NCT02926833 - Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

January 12, 2023

Study Completion Date

January 12, 2023

Conditions

Refractory Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL

KTE-C19

A single infusion of KTE-C19 CAR-T cells administered intravenously

BIOLOGICAL

Atezolizumab

Administered intravenously

DRUG

Cyclophosphamide

Administered intravenously

DRUG

Fludarabine

Administered intravenously

Trial Locations (5)

H Lee Moffitt Cancer Center, Tampa

University of Texas MD Anderson Cancer Center, Houston

City of Hope, Duarte

Stanford Cancer Center, Palo Alto

Dana Farber Cancer Institute, Boston